ArticleFrontiers in oncology2024

KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies.

Lara V Graham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.